http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Scholar Rock Holding Corp. (SRRK) Reports $25M Milestone Payment from Strategic Fibrosis Collaboration with Gilead Sciences (GILD)
-
Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences
-
Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences
-
Scholar Rock Added to NASDAQ Biotechnology Index
-
Scholar Rock Added to NASDAQ Biotechnology Index
-
Scholar Rock Reports Third Quarter 2019 Financial Results and Highlights Business Progress
-
Scholar Rock Reports Third Quarter 2019 Financial Results and Highlights Business Progress
-
Scholar Rock to Present at the 2019 Jefferies London Healthcare Conference
-
Scholar Rock to Present at the 2019 Jefferies London Healthcare Conference
-
Scholar Rock to Present Preclinical and Phase 1 Clinical Data on SRK-015 at the World Muscle Society Congress
-
Scholar Rock to Present Preclinical and Phase 1 Clinical Data on SRK-015 at the World Muscle Society Congress
-
Scholar Rock Announces Appointment of George Nomikos, M.D., Ph.D., as Vice President, Head of Medical Research, Muscle Franchise
-
Scholar Rock Announces Appointment of George Nomikos, M.D., Ph.D., as Vice President, Head of Medical Research, Muscle Franchise
-
Scholar Rock to Present at Upcoming Healthcare Conferences
-
Scholar Rock to Present at Upcoming Healthcare Conferences
-
Scholar Rock Holding Corp. (SRRK) Reports Upcoming Departure of CFO Rhonda Chicko, Effective Sept. 30, 2019; Initiates Search for New CFO
-
Scholar Rock Announces Upcoming Departure of Chief Financial Officer
-
Scholar Rock Announces Upcoming Departure of Chief Financial Officer
-
Scholar Rock Reports Second Quarter 2019 Financial Results and Highlights Business Progress
-
Scholar Rock Reports Second Quarter 2019 Financial Results and Highlights Business Progress
-
Scholar Rock to Present at the 2019 Wedbush PacGrow Healthcare Conference
-
Scholar Rock to Present at the 2019 Wedbush PacGrow Healthcare Conference
-
Scholar Rock to Present at the 2019 BMO Prescriptions for Success Healthcare Conference
-
Scholar Rock to Present at the 2019 BMO Prescriptions for Success Healthcare Conference
-
Scholar Rock Holding Corp. (SRRK) Reports Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers
-
Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers
-
Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers
-
Scholar Rock to Present at the Jefferies 2019 Global Healthcare Conference
-
Scholar Rock to Present at the Jefferies 2019 Global Healthcare Conference
-
Scholar Rock Reports First Quarter 2019 Financial Results and Highlights Business Progress
-
Scholar Rock Reports First Quarter 2019 Financial Results and Highlights Business Progress
-
Scholar Rock Holding Corp. (SRRK) Commences Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy
-
Scholar Rock Announces Initiation of Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy
-
Scholar Rock Announces Initiation of Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy
-
Scholar Rock Holding Corp. (SRRK) Names Akshay Vaishnaw, M.D., Ph.D. to Board
-
Scholar Rock Appoints Akshay Vaishnaw, M.D., Ph.D. to Its Board of Directors
-
Scholar Rock Appoints Akshay Vaishnaw, M.D., Ph.D. to Its Board of Directors
-
Scholar Rock Announces Appointment of Lisa Amaya Price as Senior Vice President, Human Resources
-
Scholar Rock Announces Appointment of Lisa Amaya Price as Senior Vice President, Human Resources
-
Scholar Rock Presents Additional Preclinical Data Demonstrating a Highly Specific Inhibitor of TGFβ1 Activation Can Render Resistant Solid Tumors Vulnerable to PD1 Blockade and Drive Tumor Regression
-
Scholar Rock Presents Additional Preclinical Data Demonstrating a Highly Specific Inhibitor of TGFβ1 Activation Can Render Resistant Solid Tumors Vulnerable to PD1 Blockade and Drive Tumor Regression
-
Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress
-
Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress
-
Scholar Rock to Develop Cancer Immunotherapy Product Candidate, SRK-181, a Selective Inhibitor of TGFβ1 Activation, to Overcome Checkpoint Inhibitor Resistance
-
Scholar Rock to Develop Cancer Immunotherapy Product Candidate, SRK-181, a Selective Inhibitor of TGFβ1 Activation, to Overcome Checkpoint Inhibitor Resistance
-
Scholar Rock to Participate in Upcoming Investor Conferences
-
Scholar Rock to Participate in Upcoming Investor Conferences
-
Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans
-
Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans
-
Scholar Rock to Present at the 37th Annual J.P. Morgan Healthcare Conference

